Pfizer just paid a lot of cash to catch up in the GLP race. Why its stock is higher

(PRO Views are exclusive to PRO subscribers, giving them insight on the news of the day direct from a real investing pro. See the full discussion above.) Pfizer is spending more than $7 billion to buy biotech Metsera to try to catch cup in the obesity drug market. Investors reacted by bidding shares of Pfizer higher in Monday morning trading, an atypical reaction to when a company is coughing up a big chunk of dough for an acquisition. "Getting into GLP land... it's kind of been the Holy Grail for everybody," said Tim Seymour of Seymour Asset Management in a special video for CNBC Pro (see above) . "I think's it's not surprising to see Pfizer rallying this morning because they had scrapped their own plans in GLP about five months ago." PFE 1D mountain Pfizer, 1 day "Pfizer, over the course